Is Your Site Selection Process Optimized?
By Erin Stanley, Halloran Consulting Group, Inc.
If 2020 has amplified anything for us, it’s that running a clinical trial is complicated. And for what feels like the first time in a long time, the entire world has eyes on our industry. We’ve been presented with the opportunity and demand to change the status quo across protocol design, patient experience, and clinical monitoring, just to name a few. And another important topic that must be revisited is the site selection process.
The numbers behind clinical trial performance are not favorable, with 70% of trials experiencing start-up delays, nearly 80% of trials failing to meet on-time enrollment, and 45% of trials completing beyond original projected timelines.